Roots Analysis has done a detailed report on Subcutaneous
Biologics, Technologies and Drug Delivery Systems (3rd Edition),
2020-2030”
Key Market Insights
§
§
§
§
§
§
§
§
§
§
For more information,
please visit https://www.rootsanalysis.com/reports/view_document/subcutaneous-biologics-delivery/314.html or
email sales@rootsanalysis.com
Table of Contents
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Types of Therapeutic
Molecules
3.3. Biologically Derived
Therapeutics
3.3.1. Types of Products
3.3.2. Routes
of Administration and Formulations
3.3.3. Subcutaneous Formulations
3.3.3.1. Approaches
in Subcutaneous Delivery of Biologics
3.3.3.1.1. Reformulation
3.3.3.1.2. Differing Potencies
3.3.3.1.3. Novel Technologies
3.3.3.2. Method
of Subcutaneous Administration
3.3.3.3. Advantages
of Subcutaneous Administration
3.3.3.4. Limitations
of Subcutaneous Administration
3.4. Regulatory Considerations
3.4.1. Medical Devices
3.4.2. Drug Device Combination Products
3.5. Future Perspectives
4. SUBCUTANEOUS BIOLOGICS:
CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Subcutaneous Administration of
Biologics
4.3. Subcutaneous Biologics: List
of Approved Drugs
4.3.1. Analysis by Approval Year
4.3.2. Analysis by Type of
Pharmacological Molecule
4.3.3. Analysis by Target Therapeutic
Area
4.3.4. Analysis by Type of Formulation
4.3.5. Analysis by Dosing Frequency
4.3.6. Analysis by Dosage Form
4.3.7. Key Players: Analysis by Number
of Drugs Approved
4.4. Subcutaneous Biologics: List
of Clinical-Stage Drug Candidates
4.4.1. Analysis by Phase of Development
4.4.2. Analysis by Type of
Pharmacological Molecule
4.4.3. Analysis by Target Therapeutic
Area
4.4.4. Analysis by Dosing Frequency
4.4.5. Key Players: Analysis by Number
of Drug Candidates in Trials
5. CASE STUDY: LEADING
SUBCUTANEOUS BIOLOGICS
5.1. Chapter Overview
5.2. Subcutaneous Biologics:
Leading Drugs by Annual Sales
5.3. Case Studies
5.3.1. HUMIRA® (AbbVie, Eisai)
5.3.1.1. Drug
Overview
5. 3.1.2. Development History
5. 3.1.3. Target Indications and Dosage Forms
5. 3.1.4. Historical Sales
5.3.2. Enbrel® (Amgen, Pfizer, Takeda
Pharmaceutical)
5.3.2.1. Overview
5. 3.2.2. Development History
5. 3.2.3. Target Indications and Dosage Forms
5. 3.2.4. Historical Sales
5.3.3. RITUXAN® / MabThera® (Biogen,
Roche, Chugai Pharmaceutical)
5.3.3.1. Overview
5. 3.3.2. Development History
5. 3.3.3. Target Indications and Dosage Forms
5. 3.3.4. Historical Sales
5. 3.3.5. ENHANZE™ Technology (Halozyme
Therapeutics)
5.3.4. Herceptin® (Roche, Chugai
Pharmaceutical)
5.3.4.1. Overview
5. 3.4.2. Development History
5. 3.4.3. Target Indications and Dosage Forms
5. 3.4.4. Historical Sales
5. 3.4.5. ENHANZE™ Technology (Halozyme
Therapeutics)
5. 3.4.6. Advantages of Subcutaneous
Herceptin® Over Intravenous Herceptin®
5. 3.4.7. Herceptin® - Large Volume Wearable
Injector Combination Product
5.3.5. Neulasta® (Amgen, Kyowa Hakko
Kirin)
5.3.5.1. Overview
5.3.5.2. Development
History
5.3.5.3. Target
Indications and Dosage Forms
5.3.5.4. Historical
Sales
6.1. Chapter Overview
6.2. Subcutaneous Formulation Technologies:
List of Technology Developers
6.2.1. Analysis by Year of
Establishment
6.2.2. Analysis by Company Size
6.2.3. Analysis by Geographical
Location
6.3. Subcutaneous Formulation
Technologies: List of Technologies
6.3.1. Analysis by Type of Pharmacological
Molecule
6.3.2. Analysis by Route of
Administration
6.3.3. Analysis by Advantage(s) Offered
7.1. Chapter Overview
7.2. Subcutaneous Formulation
Technology Developers: Competitive Landscape
7.2.1. Methodology
7.3. Subcutaneous Formulation
Technology Developers: Benchmark Analysis
7.3.1. Methodology
7.3.2. North America
7.3.3. Europe
8.1. Chapter Overview
8.2. Adocia
8.2.1. Company Overview
8.2.2. Technology Overview
8.2.2.1. BioChaperone®
Technology
8.2.3. Product Portfolio
8.2.4. Financial Performance
8.2.5. Recent Developments and Future
Outlook
8.3. Ajinomoto Althea
8.3.1. Company Overview
8.3.2. Technology Overview
8.3.2.1. Crystalomics®
Formulation Technology
8.3.3. Product Portfolio
8.3.4. Financial Performance
8.3.5. Recent Developments and Future
Outlook
8.4. Arecor
8.4.1. Company Overview
8.4.2. Technology Overview
8.4.2.1. Arestat™
Technology
8.4.3. Product Portfolio
8.4.4. Recent Developments and Future
Outlook
8.5. Alteogen
8.5.1. Company Overview
8.5.2. Technology Overview
8.5.2.1. Hybrozyme
Technology
8.5.3. Product Portfolio
8.5.4. Recent Developments and Future
Outlook
8.6. Ascendis Pharma
8.6.1. Company Overview
8.6.2. Technology Overview
8.6.2.1. TransCon
Technology
8.6.3. Product Portfolio
8.6.4. Financial Performance
8.6.5. Recent Developments and Future
Outlook
8.7. Avadel Pharmaceuticals
8.7.1. Company Overview
8.7.2. Technology Overview
8.7.2.1. Medusa™
Technology
8.7.3. Product Portfolio
8.7.4. Financial Performance
8.7.5. Recent Developments and Future
Outlook
8.8. Camurus
8.8.1. Company Overview
8.8.2. Technology Overview
8.8.2.1. FluidCrystal®
Injection Depot Technology
8.8.3. Product Portfolio
8.8.4. Financial Performance
8.8.5. Recent Developments and Future
Outlook
8.9. Creative BioMart
8.9.1. Company Overview
8.9.2. Technology Overview
8.9.2.1. High
Concentration Formulation Technology
8.9.3. Product Portfolio
8.9.4. Recent Developments and Future
Outlook
8.10. Creative Biolabs
8.10.1. Company Overview
8.10.2. Technology Overview
8.10.2.1. Long-Acting Injectable Technology
8.10.3. Product Portfolio
8.10.4. Recent Developments and Future
Outlook
8.11. DURECT
8.11.1. Company Overview
8.11.2. Technology Overview
8.11.2.1. SABER® Platform
8.11.2.2. CLOUD™ PLATFORM
8.11.3. Product Portfolio
8.11.4. Financial Performance
8.11.5. Recent Developments and Future
Outlook
8.12. Eagle Pharmaceuticals
8.12.1. Company Overview
8.12.2. Technology Overview
8.12.2.1. Unnamed Technology
8.12.3. Product Portfolio
8.12.4. Financial Performance
8.12.5. Recent Developments and Future
Outlook
8.13. Halozyme Therapeutics
8.13.1. Company Overview
8.13.2. Technology Overview
8.13.2.1. ENHANZE® Technology
8.13.3. Product Portfolio
8.13.4. Financial Performance
8.13.5. Recent Developments and Future
Outlook
8.14. MedinCell
8.14.1. Company Overview
8.14.2. Technology Overview
8.14.2.1. BEPO® Technology
8.14.3. Product Portfolio
8.14.4. Recent Developments and Future
Outlook
8.15. Xeris Pharmaceuticals
8.15.1. Company Overview
8.15.2. Technology Overview
8.15.2.1. XeriJect™ Technology
8.15.2.2. XeriSol™ Technology
8.15.3. Product Portfolio
8.15.4. Recent Developments and Future
Outlook
8.16. Serina Therapeutics
8.16.1. Company Overview
8.16.2. Technology Overview
8.16.2.1. POZ™ Drug Delivery Technology
8.16.3. Product Portfolio
8.16.4. Recent Developments and Future
Outlook
9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Subcutaneous
Formulation Technologies: Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Most Active Players: Analysis by
Number of Partnerships
9.3.4. Regional Analysis
9.3.5. Intercontinental and
Intracontinental Agreements
10. SUBCUTANEOUS DRUG DELIVERY
SYSTEMS: CURRENT MARKET LANDSCAPE
10.1. Chapter Overview
10.2. Different Types of Subcutaneous
Drug Delivery Systems
10.3. Subcutaneous Drug Delivery
Systems: Overall Market Landscape
10.3.1. Large Volume Wearable Injectors
10.3.1.1. Overview
10.3.1.2. Current Market Landscape of Devices
for Non-insulin Biologics
10.3.1.2.1. Analysis by Stage of Development
10.3.1.2.2. Analysis by Type of Device
10.3.1.2.3. Analysis by Type of Dose Administered
10.3.1.2.4. Analysis by Volume / Storage Capacity
10.3.1.2.5. Analysis by Usability
10.3.1.2.6. Analysis by Mode of Injection
10.3.1.2.7. Analysis by Mechanism of Action
10.3.1.2.8. Most Active Players: Analysis by Number
of Devices
10.3.1.2.9. Product Competitiveness Analysis
10.3.1.3.2. Analysis by Type of Device
10.3.1.3.3. Analysis by Volume / Storage Capacity
10.3.1.3.4. Analysis by Usability
10.3.1.3.5. Analysis by Availability of Integrated
CGM / BGM System
10.3.1.3.6. Most Active Players: Analysis by Number
of Devices
10.3.1.3.7 Product Competitiveness Analysis
10.3.2. Autoinjectors
10.3.2.1. Overview
10.3.2.2. Current Market Landscape
10.3.2.2.1. Analysis by Usability
10.3.2.2.2. Analysis by Type of Primary Container
10.3.2.2.3. Analysis by Volume / Storage Capacity
10.3.2.2.4. Analysis by Type of Dose
10.3.2.2.5. Analysis by Actuation Mechanism
10.3.2.2.6. Most Active Players: Analysis by Number
of Devices
10.3.2.2.7. Product Competitiveness Analysis
10.3.2.3. Drug Device Combination Products
10.3.3. Pen Injectors
10.3.3.1. Overview
10.3.3.2. Current Market Landscape
10.3.3.2.1. Analysis by Usability
10.3.3.2.2. Analysis by Volume / Storage Capacity
10.3.3.2.3. Analysis by Type of Dose
10.3.3.2.4. Most Active Players: Analysis by Number
of Devices
10.3.3.3. Drug Device Combination Products
10.3.4. Needle-Free Injection Systems
10.3.4.1. Overview
10.3.4.2. Current Market Landscape
10.3.4.2.1. Analysis by Stage of Development
10.3.4.2.2. Analysis by Volume / Storage Capacity
10.3.4.2.3. Analysis by Usability
10.3.4.2.4. Analysis by Actuation Mechanism
10.3.4.2.5. Most Active Players: Analysis by Number
of Devices
10.3.4.2.6. Product Competitiveness Analysis
10.3.5. Drug Reconstitution Delivery
Systems
10.3.5.1. Overview
10.3.5.2. Current Market Landscape
10.3.5.2.1. Analysis by Usability
10.3.5.2.2. Analysis by Type of Device
10.3.5.2.3. Analysis by Type of Drug Container
10.3.5.2.4. Most Active Players: Analysis by Number
of Devices
10.3.6. Prefilled Syringes
10.3.6.1. Overview
10.3.6.2. Current Market Landscape
10.3.6.2.1. Analysis by Barrel Fabrication Material
10.3.6.2.2. Analysis by Number of Barrel Chambers
10.3.6.2.3. Analysis by Type of Needle System
10.3.6.2.4. Analysis by Volume / Storage Capacity
10.3.6.3.5. Most Active Players: Analysis by Number
of Devices
10.3.6.3. Product Competitiveness Analysis
10.3.6.4. Drug Device Combination Products
10.3.7. Implants
10.3.7.1. Overview
10.3.7.2. Current Market Landscape
10.3.7.2.1. Analysis by Stage of Development
10.3.7.2.2. Analysis by Target Therapeutic Area
10.3.7.2.3. Analysis by Implant Material
10.3.7.2.4. Analysis by Treatment Duration
10.3.7.2.5. Most Active Players: Analysis by Number
of Devices
11. SWOT ANALYSIS
11.1. Chapter Overview
11.2. Comparison of SWOT Factors
11.2.1. Strengths
11.2.2. Weaknesses
11.2.3. Opportunities
11.2.4. Threats
12. MARKET FORECAST AND
OPPORTUNITY ANALYSIS
12.1. Chapter Overview
12.2. Subcutaneous Biologics Market
12.2.1. Forecast Methodology and Key
Assumptions
12.2.2. Overall Subcutaneous Biologics
Market, 2020-2030
12.2.2.1. Subcutaneous Biologics Market,
2020-2030:Distribution by Phase of Development
12.2.2.3. Subcutaneous Biologics Market,
2020-2030:Distribution by Target Therapeutic Area
12.2.2.4. Subcutaneous Biologics Market,
2020-2030:Distribution by Key Geographical Regions
12.3. Subcutaneous Drug Delivery
Systems Market
12.3.1. Device Type 1: Large Volume
Wearable Injectors
12.3.1.1. Forecast Methodology and Key
Assumptions
12.3.1.2. Global Large Volume Wearable
Injectors Market for Non-Insulin Drugs, 2020-2030
12.3.1.3. Global Large Volume Wearable
Injectors Market for Insulin , 2020-2030
12.3.2. Device Type 2: Autoinjectors
12.3.2.1. Forecast Methodology and Key
Assumptions
12.3.2.2. Global Autoinjectors Market,
2020-2030
12.3.2.2.1. Global Autoinjectors Market:
Distribution by Usability, 2020-2030
12.3.2.2.3. Global Autoinjectors Market:
Distribution by Key Geographical Regions, 2020-2030
12.3.3. Device Type 3: Prefilled Syringes
12.3.3.1. Forecast Methodology and Key Assumptions
12.3.3.2. Global Prefilled Syringes Market,
2020-2030
12.3.3.2.2. Global Prefilled Syringes Market:
Distribution by Type of Chamber System, 2020-2030
12.3.3.2.4. Global Prefilled Syringes Market:
Distribution by Target Therapeutic Area, 2020-2030
12.3.3.2.5. Global Prefilled Syringes Market:
Distribution by Key Geographical Regions, 2020-2030
12.3.4. Device Type 4: Needle-Free
Injection Systems
12.3.4.1. Forecast Methodology and Key
Assumptions
12.3.4.2. Global Needle-Free Injection Systems
Market, 2020-2030
12.3.4.2.1. Global Needle-Free Injection Systems
Market: Distribution by Usability, 2020-2030
12.3.5. Device Type 5: Novel Drug
Reconstitution Systems
12.3.5.1. Forecast Methodology and Key
Assumptions
12.3.5.2. Global Novel Drug Reconstitution
Systems Market, 2020-2030
12.4. Subcutaneous Formulation
Technologies Market
13. CONCLUDING REMARKS
14. EXECUTIVE INSIGHTS
14.1. Chapter Overview
14.2. Lindy
Biosciences
14.2.1. Company
Snapshot
14.2.2. Interview
Transcript: Deborah Bitterfield, Chief Executive Officer and Founder
14.3. Oval
Medical Technologies
14.3.1. Company
Snapshot
14.3.2. Interview
Transcript: Matthew Young, Chief Technology Officer and Founder
14.4. Xeris
Pharmaceuticals
14.4.1. Company
Snapshot
14.5. DALI
Medical Devices
14.5.1. Company
Snapshot
14.5.2. Interview
Transcript: David Daily, Chief Executive Officer and Co-Founder
14.6. Excelse
Bio
14.6.1. Company
Snapshot
14.6.2. Interview
Transcript: Michael Reilly, Chief Executive Officer and Co-Founder
14.7. i-novion
14.7.1. Company
Snapshot
14.7.2. Interview
Transcript: Poonam R Velagaleti, Co-Founder
14.8. Enable
Injections
14.8.1. Company
Snapshot
14.8.2. Interview
Transcript: Michael Hooven, Chief Executive Officer
14.9. Immunovaccine
Technologies
14.9.1. Company
Snapshot
14.9.2. Interview
Transcript: Frederic Ors, Chief Executive Officer
14.10. Portal
Instruments
14.10.1. Company Snapshot
14.10.2. Interview Transcript: Patrick
Anquetil, Chief Executive Officer
14.11. Elcam
Medical
14.11.1. Company Snapshot
14.11.2. Interview Transcript: Menachem
Zucker, Vice President and Chief Scientist
14.12. West
Pharmaceutical Services
14.12.1. Company Snapshot
14.13. MedinCell
14.13.1. Company Snapshot
14.13.2. Interview Transcript: David Heuzé,
Communication Leader
15. APPENDIX 1: TABULATED DATA
16. APPENDIX 2: LIST OF
COMPANIES AND ORGANIZATION
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415